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Introduction {#sec001}
============

Rheumatoid arthritis (RA) is a progressive disease characterized by inflammation of synovial tissue with symmetric involvement of peripheral joints of the hand, feet, and wrists\[[@pone.0205013.ref001],[@pone.0205013.ref002]\]. The prevalence of RA ranges from 0.4% to 1.3% \[[@pone.0205013.ref003]\]. RA not only contributes to reduced survival, health related quality of life (HRQOL), activities of daily living and work productivity, but is also associated with higher health resource utilization and costs compared to general population and osteoarthritis patients \[[@pone.0205013.ref004]--[@pone.0205013.ref007]\]. Most RA-related direct costs are associated with biologic disease modifying anti-rheumatic drugs (bDMARDs), which have improved outcomes in RA patients \[[@pone.0205013.ref008]--[@pone.0205013.ref011]\]. Since the introduction of these agents, our knowledge of RA as a disease has greatly increased and new therapies as well as combination therapies (of different bDMARDs or of bDMARDs in combination with synthetic (sc)DMARDs) targeting multiple immune pathways are being developed \[[@pone.0205013.ref012],[@pone.0205013.ref013]\]. The development of novel interventions is accompanied by the introduction of bioequivalents or biosimilars of existing bDMARDs. In an environment featuring multiple therapeutic options to manage RA patients on one side and constrained health resources on the other, cost-effectiveness models that enable more precise estimations of cost and benefits could reduce the risk of inefficient resource allocation.

The framework for cost-effectiveness models for treatments in RA has evolved since first published in early 2000s, with the introduction of bDMARDs \[[@pone.0205013.ref014],[@pone.0205013.ref015]\]. The current modeling approach has served to establish economic benefits of bDMARDs in most countries, in moderate to severe RA patients with inadequately respond to methotrexate \[[@pone.0205013.ref016],[@pone.0205013.ref017]\]. In our opinion previously, published models have potential room for improvement in six areas. First, current models base treatment response on composite measures of disease activity such as European League Against Rheumatism (EULAR) response \[[@pone.0205013.ref018]\], American College of Rheumatology (ACR) response \[[@pone.0205013.ref019]\], and Disease Activity Scores in 28 joints C-reactive protein (DAS28-CRP) \[[@pone.0205013.ref020]\]. These disease activity measures are not aligned to guideline-recommended target measures of remission and hence cannot evaluate the cost-effectiveness of policies designed to implement treatment guideline-based targets \[[@pone.0205013.ref021],[@pone.0205013.ref022]\]. In addition, these measures are biased (favorably) to certain therapeutic interventions that disproportionately impact individual components of the composite measure for example CRP with interleukin-6 (IL-6) inhibitors; this is discussed further in results section under new conceptual model \[[@pone.0205013.ref023]\].

Second, disease progression in these models is based on physical functioning measured by the Health Assessment Questionnaire (HAQ) \[[@pone.0205013.ref024]\]. HAQ changes are related to inflammatory disease activity in early RA and predominately to structural damage in longstanding RA. Thus more rapid decline in HAQ on treatment is observed in patients with RA of recent onset, compared to those with established RA \[[@pone.0205013.ref025]\]. The greater reduction in HAQ observed with treatments in patients with early versus established RA highlights the ceiling effect of HAQ and thus may be insensitive to beneficial treatment effects.

Third, contemporary models derive utility scores from the HAQ, based on mapping algorithms. Nonlinear models are now recommended, and overall mapping of HAQ to European Quality of life 5 dimension (EQ-5D) \[[@pone.0205013.ref026]\] has been improved by including disease activity and pain in these models \[[@pone.0205013.ref027],[@pone.0205013.ref028]\]. However, no study (to our knowledge) has evaluated the impact of other dimensions of RA or of different composite measures on utility scores.

Fourth, certain baseline characteristics, such as age, gender, and HAQ score, are accounted for in current models. However, most of these models do not report incremental cost-effectiveness ratios (ICERs) according to important subgroups. Recent studies have evaluated ICER within a limited number of RA subgroups \[[@pone.0205013.ref029],[@pone.0205013.ref030]\].

Fifth, current modeling approaches focus on joint-related outcomes in RA, largely at the expense of extra-articular manifestations. Extra-articular manifestations occur in 18% to 41% of patients with RA \[[@pone.0205013.ref031]--[@pone.0205013.ref035]\]. A growing body of evidence---mainly derived from observational databases and registries---suggests that specific RA therapies, including methotrexate and bDMARDs, may reduce the risk of extra-articular cardiovascular disease \[CVD\] manifestations with RA \[[@pone.0205013.ref036],[@pone.0205013.ref037]\].

Sixth and finally, long-term treatment discontinuation in current models is based on real-world registry data, and these models allow for patients to cycle through tumor necrosis factor inhibitor (TNF-i) via limited sequential use of bDMARDs \[[@pone.0205013.ref028],[@pone.0205013.ref038]\]. However, these same models do not allow for data in which health providers escalate doses or re-initiate bDMARDs once treatment has been discontinued or stopped if the patient experiences a flare \[[@pone.0205013.ref039]\]. These factors may result in underestimating both increasing therapeutic benefits and costs. Although contemporary RA therapy is moving toward lowering the dose of the bDMARDs in patients once they have attained a predefined target disease activity state, such dose de-escalation is not incorporated in previously reported models \[[@pone.0205013.ref040]--[@pone.0205013.ref043]\].

Taken together, these factors point to unmet needs related to pharmacoeconomic modeling in RA. Consideration of these aspects in future economic modeling of RA treatments could enable evaluation of costs and benefits of therapies in manner that reflects prevailing clinical realities with the aim of producing more accurate cost-effectiveness estimates. The objective of this analysis was to review current economic models in RA and propose a revised conceptual model framework.

Methods {#sec002}
=======

In developing the conceptual model, the recommendations outlined by the International Society of Pharamacoeconomic and Outcomes Research-Society of Medical Decision Making (ISPOR-SMDM) Modeling Good Research Practices Task Force-2 were followed \[[@pone.0205013.ref044]\]. As depicted in [Fig 1](#pone.0205013.g001){ref-type="fig"}, the process involved scoping out the decision problem by a working group and drafting a preliminary cost effectiveness model framework. A systematic literature review (SLR) of existing decision-analytic models was performed and analysis of a RA registry was conducted to inform the structure of the draft conceptual model. Finally, an expert panel was convened to seek input on the draft conceptual model.

![Schematic overview of the development process of the conceptual model.](pone.0205013.g001){#pone.0205013.g001}

Scoping {#sec003}
-------

The knowledge gaps in current models as explained in the introduction were elucidated in a three-member (EA, MA, MR) working group. The working group focused on various aspects of the model, such as 1) measures to access treatment responses/treatment targets, 2) measure to assess RA disease progression, 3) utility mapping, 4) RA subgroups, 5) treatment patterns (e.g. dose escalation, dose de-escalation) 6) extra-articular outcomes, and mortality. Based on these aspects the working group put together a list of revisions of existing models ([S1 Appendix](#pone.0205013.s001){ref-type="supplementary-material"}) and drafted a conceptual model ([S2 Appendix](#pone.0205013.s002){ref-type="supplementary-material"}). The draft conceptual model was based on the working group analyses of a RA registry to explore treatment targets and extra-articular manifestation of RA, and RA subgroups, which have been published elsewhere \[[@pone.0205013.ref045]--[@pone.0205013.ref048]\]. In addition, the working group relied on literature and knowledge of clinical guidelines to inform model development.

SLR {#sec004}
---

A review of existing decision-analytic models on the cost-effectiveness of RA therapies published in English since 2006 was conducted as part of the scoping process. The search strategy is depicted in [S3 Appendix](#pone.0205013.s003){ref-type="supplementary-material"}. Primary searches were conducted in Medline, EMBASE, and EconLit simultaneously using Ovid based on the search strategy outlined. In addition to the SLR, recent publication on methodologies of economic modeling in RA was also reviewed \[[@pone.0205013.ref049]\]. To supplement the database search, a manual search of previous health technology assessment (HTA) reports was conducted on the UK National Institute for Health and Clinical Excellence website (<https://www.nice.org.uk/guidance/ta375/history> \[last accessed Nov 2017\]). The primary objective of the SLR was to identify published economic evaluations of bDMARDs in RA. The SLR focused on model structure, short-term treatment targets/responses, RA disease progression (long-term response when initial treatment is successful), utility mapping, patient subgroups (with characteristics that could be treatment effect modifiers), treatment aspects (switching, dose escalation, de-escalation), time horizon, and mortality associated with RA.

Analysis to inform conceptual model {#sec005}
-----------------------------------

To inform disease progression and utility mapping in the conceptual model, the working group conducted a retrospective analysis of a RA registry. A longitudinal sequential registry of primarily established RA patients was used for this analysis. In this registry, disease activity was measured annually during rheumatology visits using multiple composite functional measures \[[@pone.0205013.ref050]\]. These included the DAS28-CRP, Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) \[[@pone.0205013.ref051]\]. The generic HRQOL index EQ-5D was evaluated every 6 months via both mailed questionnaires and in-person interview (during annual visit). The progression of RA using various composite measures as well as changes in these disease activity over time was evaluated using general linear models. Mapping algorithms based on DAS28-CRP, SDAI, and CDAI were compared to the physical functioning (HAQ)-based mapping algorithm. Fixed-effects models were used to estimate the best predictors of EQ-5D, because within-patient variability over time is more important than between patient variability in economic models \[[@pone.0205013.ref052]\].

Expert panel {#sec006}
------------

An expert panel comprising two rheumatologist (AB, MW), one health economist (MS), and two epidemiologists/health services researchers (KM, SV) was convened to provide input to the conceptual model. The draft conceptual model was presented to each expert in a multistep approach. In the first step, a member of the working group (EA) shared the discussion guide developed by the working group with the expert panel members. The discussion guide contained an overview and limitations of current modeling approaches in RA as well as the proposed conceptual model structure. It also included a brief questionnaire that focused on the proposed modifications to the cost-effectiveness model. In the second step, opinions from all experts of the panel were gathered via individual interviews. The third step involved updating the draft conceptual model and collating all responses to questions and comments. The revised document was shared with all experts for additional inputs. Additional updates were then incorporated, and the conceptual model was sent back to the panel for a final opportunity to provide suggestions.

Results {#sec007}
=======

Scoping {#sec008}
-------

The decision problem that the conceptual model would address was defined as identifying cost-effective drug interventions for moderate-to-severe RA that result in the most health benefits for the overall RA population as well as for specific subgroups (such as those with poor prognostic factors). This includes current and novel interventions that are being developed and may be introduced in clinical practice in the future as monotherapy or combination therapies.

SLR {#sec009}
---

A total of 32 economic evaluation studies were identified by the initial SLR, 5 of which were review articles. The remaining 27 manuscripts evaluated are summarized in [S3 Appendix](#pone.0205013.s003){ref-type="supplementary-material"} Table 3 \[[@pone.0205013.ref029],[@pone.0205013.ref038],[@pone.0205013.ref049]--[@pone.0205013.ref077]\]. The primary model structures were cohort based or individual patient simulations, which included discrete event simulations and individual patient Markov models. More recent published models tended to be primarily individual patient simulations.

The assumed relationship between different model variables is summarized in the influence diagram represented in [Fig 2](#pone.0205013.g002){ref-type="fig"}. Each solid arrow represents a direct effect of one variable on the other, while the dashed lines represent the mathematically derived structural relationships. In general, these models evaluate short-term (3 to 6 months) treatment effects based on clinical trial efficacy. Based on the short-term efficacy and probability of adverse events (AEs), a decision rule was included in the model for a patient to continue treatment or not. If treatment is continued, then disease progression is estimated based on HAQ change over time. In recent models HAQ change over time is based on mixture models, while earlier models used linear progression (0 per annum for bDMARDs and 0.03 to 0.045 per annum for cDMARDs) \[[@pone.0205013.ref029],[@pone.0205013.ref064]\]. HAQ scores are then mapped to HRQOL, mortality rates and resource use, using mapping algorithms. The long-term treatment duration in the majority of the simulation models is based on real-world registry data, extrapolated using survival models with time to treatment discontinuation as outcomes. The endpoint driving cost-effectiveness models in RA is primarily physical functioning, whereas other endpoints such as radiographic progression are rarely used \[[@pone.0205013.ref076]\].

![RA economic model influence diagram for structural relationship.](pone.0205013.g002){#pone.0205013.g002}

New conceptual model {#sec010}
--------------------

The conceptual model drafted by the working group is represented in [Fig 3](#pone.0205013.g003){ref-type="fig"}. The proposed conceptual model is an individual patient simulation model with a lifetime horizon proposed to capture short-term and long-term benefits and cost of interventions. Outcomes are defined as quality-adjusted life years (QALYs) and life-years gained (LYG). This model is intended for HTA and is based on the payer's perspective and has three distinct modules: 1) *patient characteristic module*, 2) *treatment module* and 3) *outcome module*. This framework enables addressing issues of treatment responses, RA subgroups, real world treatment patterns and extra-articular manifestation of RA mentioned in the introduction. This proposed conceptual model should be seen as "aspirational" because not all data elements required to populate the model are available (at the time of writing) but are likely to become available in the future. The ISPOR-SMDM Modeling Good Research Practices Task Force-2 stresses that conceptual models should not be driven solely by the presence or absence of clinical data \[[@pone.0205013.ref044]\].

![Draft conceptual model to evaluate cost effectiveness in RA.](pone.0205013.g003){#pone.0205013.g003}

To improve the clinical relevance of the economic models in RA, it is important to align treatment responses to guideline-recommended targets, which are based on composite measures of disease activity \[[@pone.0205013.ref021],[@pone.0205013.ref022]\]. The working group proposed the expert panel to consider CDAI as a measure of treatment response in the conceptual model (change 1a). This was primarily based on observed associations between treatment targets and outcomes of physical functioning (HAQ), HRQOL (i.e. EQ-5D), and health resource use. A greater improvement was observed in these outcomes among patients attaining (vs. not attaining) a CDAI based target, compared to SDAI and DAS28-CRP based targets \[[@pone.0205013.ref047]\]. In addition, CDAI has acceptable psychometric properties, including validity and sensitivity to change \[[@pone.0205013.ref078]--[@pone.0205013.ref081]\]. CDAI remission does not include levels of CRP or erythrocyte sedimentation rate (ESR) which are primarily impacted by therapies such as IL-6 and janus kinase inhibitors. Thus, the new conceptual model could include a CDAI score of \<2.8 (remission) or ≤10 (LDA) as a definition for responder for treatment continuation. In terms of disease progression, the working group proposed CDAI change over time (change 1b). This was based on analysis of changes in CDAI, SDAI and DAS28-CRP in a cohort of patients with mostly established RA \[[@pone.0205013.ref050]\]. Results of these analyses indicate that response to change over time is dependent on disease duration and measurement of disease activity under consideration ([S4 Appendix](#pone.0205013.s004){ref-type="supplementary-material"}).

Finally, the mapping exercise of disease activity measures and physical functioning to EQ-5D indicates that mapping models predicated on CDAI and Routine Assessment of Patient Index Data-3 (RAPID-3) measures have the best fit according to *r*^2^ and root mean square error values ([Table 1](#pone.0205013.t001){ref-type="table"}). RAPID-3 is an index of physical function, patient pain, and patient global, and as such a PRO index of disease activity (or impact). Based on these findings, the working group proposed to the expert panel that the conceptual framework should include utilities based on disease activity measure (CDAI) and RAPID-3 (change 2).

10.1371/journal.pone.0205013.t001

###### Fixed effects regression models for EQ5D.

![](pone.0205013.t001){#pone.0205013.t001g}

  Models                                                                      R-Square   Root MSE   F- value
  --------------------------------------------------------------------------- ---------- ---------- ----------
  Patient global, Patient pain scale RADAI Joint Score                        0.70       0.09       14.2
  RAPID3, RADAI Joint Score                                                   0.72       0.09       14.3
  RAPID3                                                                      0.71       0.09       13.8
  **RAPID3, CDAI**                                                            **0.75**   **0.09**   **7.4**
  mHAQ                                                                        0.68       0.10       15.4
  mHAQ, RADAI Joint Score                                                     0.70       0.09       16.7
  mHAQ, CDAI                                                                  0.71       0.09       7.8
  mHAQ, mHAQ square                                                           0.68       0.10       15.4
  mHAQ, pain                                                                  0.70       0.09       14.4
  mdHAQ, RADAI Joint Score                                                    0.70       0.09       17.0
  mdHAQ                                                                       0.68       0.10       15.8
  **Models with baseline co-variates of age, duration, CRP and serostatus**                         
  Patient global, Patient pain scale RADAI Joint Score                        0.74       0.09       7.5
  RAPID3, RADAI Joint Score                                                   0.73       0.09       15.1
  RAPID3                                                                      0.71       0.09       14.0
  **RAPID3, CDAI**                                                            **0.75**   **0.09**   **7.4**
  mHAQ                                                                        0.68       0.10       15.4
  mHAQ, RADAI Joint Score                                                     0.69       0.09       16.7
  mHAQ, CDAI                                                                  0.71       0.09       7.8
  mHAQ, mHAQ square                                                           0.68       0.10       15.4
  mHAQ, pain                                                                  0.70       0.09       14.5
  mdHAQ, RADAI Joint Score                                                    0.70       0.09       14.6
  mdHAQ                                                                       0.68       0.10       15.7

Based on current evidence, the conceptual model accommodates subgroups with a high risk of disease progression such as those with multiple prognostic factors (change 3). Additional subgroups that the working group considered important for inclusion were patients with susceptible to infections. The *patient characteristic module* accounts for patient characteristics when entering the model and at subsequent time points. This module enables risk stratification of RA patients based on prognostic factors. Some commonly reported prognostic factors for a more rapid and aggressive disease are double seropositivity for anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid factor (RF), as well as erosions, disease activity and measures of inflammation (CRP/ESR) \[[@pone.0205013.ref081]--[@pone.0205013.ref085]\]. There is evidence that certain prognostic factors can be considered as treatment effect modifiers \[[@pone.0205013.ref086]--[@pone.0205013.ref088]\]. Subgroups based on patients' risks of infections were considered, RA patients with high disease activity also have increased risk of infections as well as CVD \[[@pone.0205013.ref089],[@pone.0205013.ref090]\]. In addition, evidence indicates that glucocorticoids and certain DMARDs increase the risk of infection in RA patients \[[@pone.0205013.ref091],[@pone.0205013.ref092]\] and because prevalent RA patients tend to be elderly and thus at increased risk for infections.

*The treatment module* accommodates all treatment changes (change 4), in patients who do not attain remission or low disease activity (LDA) or patients who experience AEs within 3 to 6 months (or secondary failure) after treatment initiation. In addition, the proposed conceptual model allows for flexibility in dose escalation. Data from observational studies have shown that some patients require upward dose adjustments, reduced dose interval for bDMARDS, or addition of glucocorticoids and/or nonsteroidal anti-inflammatory drugs (glucocorticoids/NSAIDs) to some bDMARDs in order to achieve or maintain a clinical response \[[@pone.0205013.ref093],[@pone.0205013.ref094]\]. Upward dose adjustments are associated with increased medication costs and potentially adverse reactions. Dose escalation is not in the summary of the product characteristics of any of the current approved DMARDs.

*The outcome module* incorporates disease progression and its impact on both joint and extra-articular outcomes. The conceptual model accommodates extra-articular disease outcomes, principally CVD events (change 5). These events were considered by the working group primarily based on available epidemiologic data, as well as on the treatment effects and the cost implications of these outcomes. The working group proposed incorporation of RA-specific mortality risk based on disease activity in the economic model once more data becomes available (change 6).

Expert panel {#sec011}
------------

Members of the expert panel debated the draft model structure, challenging the level of evidence to support several proposed changes. Nevertheless, a majority of the panel agreed that the model should enable subgroup analysis by prognostic factors, and also investigate the need to accommodate increased risk of infection (change 3). The experts agreed on QALYs should be the main outcome and, mortality based on RA disease activity (change 6). In addition, there was agreement on further exploring the impact of including extra-articular manifestations on ICERs (change 5).

The expert panel also acknowledged the advantage of having a disease activity measure for both treatment response and disease progression (change 1). Questions were raised on CDAI data availability from historic phase 3 programs and concerns were mentioned about the subjective elements of CDAI, such as estimation of tender joint counts, patient and physician global health, which are unweighted and can make the measure less reliable. At the same time, the members of the expert panel acknowledged that this perceived limitation might also apply to other currently available composite measures. The least agreement among experts was on the proposed mapping of only disease activity (change 2) to HRQOL utilities (i.e. EQ-5D). Recommendation was to explore the use of mixed logit models, based on disease activity and HAQ with other dimensions of RA such as pain, fatigue. Strengths and limitations of the recommended changes, along with expert inputs and level of agreement among experts concerning the proposed changes, are summarized in [Table 2](#pone.0205013.t002){ref-type="table"}.

10.1371/journal.pone.0205013.t002

###### Summary of pros and cons of proposed changes, expert input and agreement.

![](pone.0205013.t002){#pone.0205013.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Changes proposed                                                                          Pros and Cons                                                                                                                                                           Expert Inputs                                                                                                                                                                                                                                                                                                                                         Expert Agreement[\*](#t002fn001){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------
  Model Structure                                                                           Pros: aligned with clinical practice & guidelines; allows to captures patient subgroups, treatment heterogeneity, non-joint outcomes;\                                  Ideal, however data may not be available to populate modelInclude cDMARD-naïve and cDMARD inadequate respondersChanges may not materially impact ICERThe time involved in incorporating the changes might not be worth the extra accuracy                                                                                                             3 of 5
                                                                                            Cons: increase in complexity; data availability                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Minimum of two disease activity measures for treatment response and disease progression   Pros: Aligns to treatment guidelines; less biased estimates (vs. single measure)\                                                                                       Data availability might be an issue                                                                                                                                                                                                                                                                                                                   4 of 5
                                                                                            Con: Data availability;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Disease activity based mapping of utilities                                               Pros: Addresses the limitation of HAQ changes; Allows the model to be based entirely on disease activity; could lead to further improvements in mapping of utilities\   HAQ would still be an unbiased estimator of disease progressionReasons for HAQ was its association to cost in RAWould not recommend RAPID3 by itself as it based entirely on patient report. Good to see that we are combining disease activity and RAPID3                                                                                            3 of 5
                                                                                            Cons: Data availability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Incorporation of subgroups                                                                Pros: Allows for specific and targeted HTA evaluations\                                                                                                                 Double sero-positives are at a higher risk of progressing (vs. single positive)Patients who have erosive disease at baseline are high risk of progressionAdditional subgroups could include elderly i.e. age \>65 yrs (as they are increased risk of infections), CV and other RA extra-articular manifestationsThese are not just baseline factors   5 of 5
                                                                                            Cons: No general agreement that the prognostic factors are well established in RA; data availability                                                                                                                                                                                                                                                                                                                                                                                                                          

  Real world treatment patterns:                                                            Pros: Allows for realistic estimates of cost and clinical benefits of standard of care\                                                                                 Generalizability of real world data vs. trials (where efficacy was gained)No controlled studies have examined switching therapy in patients who are well controlledGPs behavior cannot be clearly defined and consistent for dose reduction                                                                                                           4 of 5
                                                                                            Cons: data availability;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Incorporating extra-articular manifestations of RA:                                       Pros: Allows for improved estimation of benefit and cost of interventions\                                                                                              CV and lung disease should be consideredImportant if treatment would differentially impact extra-articular manifestationsThe strength of this evidence, particularly with respect to changes in markers and changes in hard outcomes is limited                                                                                                       5 of 5
                                                                                            Cons: data availability;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Mortality Associated with RA                                                              Pros: allows for disease activity be the driver of benefits\                                                                                                            No comments                                                                                                                                                                                                                                                                                                                                           5 of 5
                                                                                            Cons: potential for overestimation of survival; data availability                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Agreement in principal that these need to be evaluated in future economic models;

IR--inadequate response; ICER = Incremental cost effectiveness ratio

After expert panel inputs had been incorporated, the draft conceptual model was further modified and these further changes are reflected in the updated conceptual model ([Fig 4](#pone.0205013.g004){ref-type="fig"}). Because there is no clinical criterion or reference standard disease activity measure, the conceptual framework was revised to incorporate at least two disease activity measures: one as a "base case" and the other for sensitivity analyses concerning treatment effect as well as disease progression (change 1). For example CDAI or SDAI or other disease activity measures could be used as the base case and DAS28-CRP for a sensitivity analysis. The updated conceptual model also includes, in the same framework, patients who have not been exposed to csDMARDs or who have not responded adequately to them. According to input from the expert panel, the conceptual model included treatment intensification (glucocorticoids and/or NSAIDs) before the patient received bDMARD switch and also dose de-escalation in patients attaining remission (change 4). The final update based on expert input was the inclusion of pulmonary extra-articular manifestation in addition to CV extra-articular effects of RA (change 5).

![Updated conceptual model to evaluate cost effectiveness in RA.](pone.0205013.g004){#pone.0205013.g004}

Discussion {#sec012}
==========

This study used a well-established methodology to propose a conceptual framework for developing future models in RA to evaluate the cost effectiveness of therapies \[[@pone.0205013.ref044]\]. The current cost effectiveness modeling framework in RA was introduced with the advent of TNF-i. Since then our knowledge of RA disease mechanism, impact on joints as well as on other organ systems has greatly increased. In addition, maturation of existing electronic medical records, claims datasets and registries enable us to better understand RA treatment patterns. Thus, the proposal of an updated conceptual model that incorporates these understandings may be timely. In proposing the conceptual model we leveraged the earlier modeling approaches as certain aspects are well established.

Overall, the proposed conceptual model reflects on 6 preselected areas of modelling cost-effectiveness of drug treatment in moderate to severe RA in the 21th century. The major changes that this conceptual model proposes are 1) use of at least two composite measures of disease activity, with one used in sensitivity analyses, to evaluate both treatment response as well as disease progression; 2) utility mapping based on disease activity 3) the consideration of subgroups based on prognostic factors and potential treatment effect modifiers 4) the incorporation of realistic treatment patterns based on clinical practice/registry datasets 5) incorporation of non-joint related (extra-articular) outcomes and 6) mortality based on disease activity.

Implementation of these structural changes could be prioritized based on the expected impact on model estimates and on availability of data to populate the model. Incorporation of subgroups based on prognostic factors ranked high on the prioritization order as this is relatively straightforward. In addition, recent cost effectiveness analyses have demonstrated the importance of incorporation of subgroups as these patients may have characteristics which are potentially effect modifiers \[[@pone.0205013.ref029],[@pone.0205013.ref030]\]. However, these analyses are still limited and further work needs to be done to understand and define RA subgroups with combinations of prognostic factors. Stratification of cost-effectiveness analysis by subgroups could have implication for targeting specific therapies or combination of therapies to certain subgroups thereby improving the overall clinical outcomes and cost. This could pave the way for policies leading to personalized medicine in RA.

The second priority is deemed to be the use of a disease activity measure, to model treatment response/stopping, disease progression, mapping of utility and mortality. The conceptual model allows for at least two disease activity measures one as base case and one as sensitivity analysis. Until an objective measure of disease activity is established in RA and used in routine clinical practice, impact of treatment on multiple disease activity measures will have to be evaluated in the same model/analysis. Though current mapping algorithms for utility use mixed models based on HAQ, pain and disease activity. We believe further research is required comparing mapping algorithms using different disease activity measures. In addition, future research should also evaluate the benefits of having direct measurement of utility from RA clinical trials or from real world studies vs. mapping EQ-5D.

Next on the priority list is the incorporation of more realistic treatment algorithms into the cost effectiveness model. Components of this proposed change such as glucocorticoids and NSAID intensification, treatment discontinuation, dose escalation can be informed by current RA registries, administrative claims and EMR database analysis. However, bDMARD dose de-escalation is a new development based on a recent de-escalation trial design \[[@pone.0205013.ref037]--[@pone.0205013.ref040]\]. Current evidence on real world dose de-escalation will be limited and hence the model will have to be informed by clinical trial data at present. The last prioritized item is the incorporation of extra-articular manifestation since more research is needed to develop RA-specific risk models for both CV and pulmonary disease however, in the interim, treatment-specific risk reduction of CV could be incorporated in sensitivity analysis.

The conceptual model presented in this manuscript concurs with some of the recommendations of the consensus recommendations from the 2015 'Consensus Working Party' such as incorporation of AE based discontinuation, mapping of utility to disease activity \[[@pone.0205013.ref095]\]. However, there are also some major differences between the Consensus Working Party's recommendation and the current proposed conceptual model. The reliance by the Consensus Working Party on DAS28 for treatment response could lead to biased estimates for therapies such as anti-IL6 that have a disproportionate impact on acute phase reactants in DAS28. Additional differences include incorporation of detailed treatment patterns versus only treatment discontinuation, specification of prognostic factors and incorporation of extra-articular manifestations.

This analysis represent the first step in a model building exercise, the appropriate next step would be to build a model prototype and evaluate the feasibility of operationalizing the proposed changes. Limitations of the current approach is that the analysis informing the conceptual model was based on data from one US registry. Additional work based on other registries, especially non-US registries, early RA registries and even registries focused on "treat to target" approaches would be informative. Additional limitations, include the scope of the conceptual model did not permit empirical evaluation of the proposed changes in reducing the current uncertainty in economic models and the reliance on EQ-5D as measure of utility. Finally, we did not evaluate the association between CDAI reduction and resource use/cost. However, there is evidence that attainment of remission and LDA is associated with lower resource utilization, higher quality of life and improved physical functioning \[[@pone.0205013.ref045]\].

Though we developed this conceptual model to meet payer/HTA needs, the focus has been on payers using cost per QALY or cost per life year gained as a metric for decision-making. Thus, our proposed model might not be applicable to address certain payer needs. For example US payers are interested in shorter time horizon with outcomes such as remission. In addition, treatment modules will have to be adapted to each country based on clinical practice data. Due to our focus on HTA bodies that consider only direct cost in economic evaluations, our model does not accommodate the indirect cost of RA into the analysis. Further work is required to specifically address modeling of cost effectiveness from the societal perspective. Finally, it was beyond the scope of this analysis to evaluate the impact of the availability of robust, comparative, head-to-head clinical trials in reducing the short-term efficacy uncertainties in economic evaluations of RA products.

Despite these limitation the conceptual model presented in this manuscript is based on a comprehensive approach that aims to incorporate both clinical and real-world evidence in the economic evaluation of RA interventions. We believe that the proposed model framework can potentially serve as a foundation for developing future cost effectiveness models in RA.
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